The cytochromes P450 (CYPs) are the main enzyme family for metabolism of therapeutic drugs. CYP3A4 is the most active drug metabolizing CYP, and it plays a prominent role in adverse drug-drug ...

Impact of single nucleotide polymorphism of cyclophosphamide metabolism gene in patients with diffuse large B-cell lymphoma on survival after chemotherapy. This is an ASCO Meeting Abstract from the ...

Previous studies 6 have shown that the CC 50 (cytotoxic concentration of the compound that reduces cell viability by 50%, which indicates the cytotoxicity of a drug) value of triptolide was 2.1 nmol/L ...

Compounds that target brain cancer have been recently developed by researchers. The team synthesized a first-of-its-kind inhibitor that prevents the activity of an enzyme called neuraminidase.

A metabolic enzyme found in the support cells surrounding tumors may hold the key to predicting which cancer patients will ...

Drugs are metabolized in the liver using several enzyme-catalyzed processes. These enzymes are collectively referred to as the hepatic microsomal enzyme system, and they are usually present in the ...

The ubiquitin–proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis. The therapeutic potential of this pathway has been validated by ...

A glycosyltransferase (GT) inhibitor with a novel mechanism of action could aid glycobiology research and drug discovery, according to a report in Nature Chemical Biology (DOI: 10.1038/nchembio.343).

Angiotensin converting enzyme inhibitors are a class of oral medications that act primarily through blockade of the angiotensin converting enzyme. This enzyme converts angiotensin I to angiotensin II.